BiotechTube

Ixekizumab + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Genital Psoriasis

Conditions

Genital Psoriasis, Psoriasis

Trial Timeline

Apr 1, 2016 → Feb 21, 2018

NCT ID
NCT02718898

About Ixekizumab + Placebo

Ixekizumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Genital Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02718898. Target conditions include Genital Psoriasis, Psoriasis.

What happened to similar drugs?

10 of 20 similar drugs in Genital Psoriasis were approved

Approved (10) Terminated (0) Active (10)
✅Risankizumab + Placebo for RisankizumabAbbVieApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT04285229Phase 3Completed
NCT03364309Phase 3Completed
NCT03129100Phase 3Completed
NCT02757352Phase 3Completed
NCT02696798Phase 3Completed
NCT02718898Phase 3Completed
NCT02584855Phase 3Completed
NCT02513550Phase 3Completed
NCT01107457Phase 2Completed

Competing Products

20 competing products in Genital Psoriasis

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27
Risankizumab + Placebo for RisankizumabAbbVieApproved
43